Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, agosto 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Prime Medicine Inc
PRME
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$3.39
0.15
4.63%
al cierre: Aug 21, 5:00 PM EST
$3.39
N/A
After hour: 7:23 PM EST
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Prime Medicine Financials
Prime Medicine (PRME) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from
Benzinga Newsdesk
PRO
Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 30 percent increase over losses of $(0.40) per share from the
Benzinga Newsdesk
PRO
Prime Medicine Expects That Its Cash, Cash Equivalents And Investments Of $213.3M As Of September 30, 2025 Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into 2027.
Benzinga Newsdesk
PRO
Prime Medicine Q3 EPS $(0.32) Misses $(0.26) Estimate, Sales $1.225M Beat $1.026M Estimate
Benzinga Newsdesk
PRO
Prime Medicine Q2 EPS $(0.41) Misses $(0.39) Estimate, Sales $1.115M Beat $750.000K Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 6.22 percent. This is a 10.87 percent increase over losses of $(0.46) per share from
Benzinga Newsdesk
PRO
Prime Medicine Q1 EPS $(0.40) Misses $(0.36) Estimate, Sales $1.45M Beat $1.05M Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.36) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.44) per share from
Benzinga Newsdesk
Privacy Manager